Update: Are 3 minds better than one? It certainly appears this could be the case, at least when it comes to clinical trials and getting the right type of participants to enroll and some forecasting to make sure the drugs will succeed. What is the target here, the big crystal ball that we all want, some upfront knowledge to keep time, money and overall costs down.
Tools to predict responses, imaging techniques are a couple of the focuses and it comes back around to personalized medicine. The only way better predicting can be done with better information up front. It was also mentioned down the road more funding may be required as well and so far no mention of current financial terms, but I would guess all 3 are going to have some major stakes involved, as the stakes are high. If some of the Crystal Ball outcomes are attained here, perhaps it will assist in bringing products to market much faster, but time will tell. One one side of the room you have biotech with drugs, and on the other side, there’s medical devices, and in the middle, the places where they all come together in some form or another. BD
July 10 (Bloomberg) -- Pfizer Inc., Merck & Co. and Eli Lilly & Co., along with a Boston-based venture capital firm, are pooling $39 million to start a research-based company aimed at speeding the discovery of new kinds of medicines. The three drugmakers and the investment firm, PureTech Ventures LLC, formed Enlight Biosciences LLC, of Boston. H. Robert Horvitz, a Nobel Prize winner from the Massachusetts Institute of Technology, is the co-founder of Enlight.
0 comments :
Post a Comment